Skip directly to content

Referencias

  1. Early J. Comprehensive management of cardiometabolic risk factors. Clin Cornerstone. 2007;8(3):69-80.
  2. Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 suppl 2):S76-S99.
  3. Rosendorff C, Black HR, Cannon CP, et al; American Heart Association Council for High Blood Pressure Research; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Epidemiology and Prevention. Circulation. 2007;115(21):2761-2788.
  4. Organización Mundial de la Salud. Global atlas on cardiovascular disease prevention and control. http://www.who.int/cardiovascular_diseases/publications/atlas_cvd/en/. Consultado el 12 de agosto de 2014.
  5. James WP. The epidemiology of obesity: the size of the problem. J Intern Med. 2008 Apr;263(4):336-352.
  6. Branca F, Nikogosian H, Lobstein T. World Health Organization Europe. The challenge of obesity in the WHO European region and the strategies for response. OMS 2007.
  7. Cannon CP. Cardiovascular disease and modifiable cardiometabolic risk factors. Clin Cornerstone. 2007;8(3):11-28.
  8. Cornier MA, Mazzone T, et al. Bariatric surgery and cardiovascular risk factors: a scientific statement from the American Heart Association. Circulation. 2011;123(15):1683-1701.
  9. Apovian CM, Gokce N. Obesity and cardiovascular disease. Circulation. 2012;125(9):1178-1182.
  10. Adams KF, Schatzkin A, Harris TB, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med. 2006;355(8):763-778.
  11. Olshansky SJ, Passaro DJ, Hershow RC, et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med. 2005;352(11):1138-1145.
  12. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world--a growing challenge. N Engl J Med. 2007;356(3):213-215.
  13. Tsigos C, Hainer V, Basdevant A, et al. Management of obesity in adults: European clinical practice guidelines. Obes Facts. 2008;1(2):106-116.
  14. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-1053.
  15. Gadde KM, Allison DB. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks. Circulation. 2006;114(9):974-984.
  16. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol. 2004;43(10):1731-1737.
  17. Ng M, Freeman MK, Fleming TD, et al. Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA. 2014;311(2):183-192.
  18. Organización Mundial de la Salud. Global status report on noncommunicable diseases 2010. Disponible en http://www.who.int/about/regions/en/. Consultado el 15 de agosto de 2014.
  19. Hughes JR. Motivating and helping smokers to stop smoking. J Gen Intern Med. 2003;18(12):1053-1557.
  20. Taylor DH Jr, Hasselblad V, Henley SJ, et al. Benefits of smoking cessation for longevity. Am J Public Health. 2002;92(6):990-996.
  21. Thompson PD, Buchner D, Pina IL, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation. 2003;107(24):3109-3116.
  22. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.
  23. Kronish IM, Ye S. Adherence to cardiovascular medications: lessons learned and future directions. Prog Cardiovasc Dis. 2013;55(6):590-600.
  24. Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary non-adherence after acute myocardial infarction. Circulation. 2008;117(8):1028-36.
  25. Kesselheim AS, Bykov K, Avorn J, et al. Burden of changes in pill appearance for patients receiving generic cardiovascular medications after myocardial infarction: cohort and nested case-control studies. Ann Intern Med. 2014;161(2):96-103.